Moderna (MRNA)
(Delayed Data from NSDQ)
$122.50 USD
+1.36 (1.12%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $122.44 -0.06 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$122.50 USD
+1.36 (1.12%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $122.44 -0.06 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Zacks News
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
by Zacks Equity Research
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
Company News For May 13, 2024
by Zacks Equity Research
Companies In The Article Are:NVAX, SNY, MRNA, G and IAG.
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
by Zacks Equity Research
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 14.48% and 33.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Moderna (MRNA)
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
Unveiling Moderna (MRNA) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $107.97, moving +1.69% from the previous trading session.
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust NASDAQ-100 Equal Weighted ETF (QQEW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QQEW
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
Moderna (MRNA) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) reachead $101.41 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.
Moderna (MRNA) Stock Moves -0.34%: What You Should Know
by Zacks Equity Research
In the latest trading session, Moderna (MRNA) closed at $103.44, marking a -0.34% move from the previous day.
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
by Zacks Equity Research
Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals are part of the Zacks top Analyst Blog.
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $107.01, moving -0.12% from the previous trading session.
Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
by Zacks Equity Research
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
by Zacks Equity Research
Moderna (MRNA) and Bristol Myers (BMY) are in focus on pipeline and regulatory updates.
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
by Zacks Equity Research
Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.
Company News for Apr 10, 2024
by Zacks Equity Research
Companies in The News Are: MRNA, MRK, COIN, BN, NEOG